Atlas Critical Minerals Stock Faces a New Test as Defense-Metals Money Rushes Into Nasdaq

Atlas Critical Minerals Stock Faces a New Test as Defense-Metals Money Rushes Into Nasdaq

May 29, 2026

NEW YORK, May 29, 2026, 07:02 EDT

Atlas Critical Minerals Corp’s U.S.-listed shares head into Friday’s regular Nasdaq session near their 52-week low, even as investors keep chasing small mining names tied to the defense supply-chain trade. ATCX closed Thursday at $4.41, up 0.9%, with a 52-week range of $4.28 to $47.16, market data showed.

The timing matters. Nasdaq’s regular session had not opened yet, with trading scheduled for 9:30 a.m. to 4 p.m. ET; May 29 is not on Nasdaq’s 2026 holiday closure list, after the Memorial Day market break on May 25.

The stock sits at the edge of a wider policy trade. Critical minerals are materials viewed as essential to the economy or national security and exposed to supply disruption; rare earths, a key subset, are used in smartphones, hard drives and advanced defense systems.

Reuters reported this week that at least 18 mining firms have completed or pursued U.S. listings in 2026, against three in 2025, as prospectuses lean harder on defense demand. Guardian Metal Resources raised $68.3 million, Rare Earth Americas raised $63.3 million and Atlas raised about $11 million; United States Antimony also secured a $245 million Defense Logistics Agency contract. Guardian CEO Oliver Friesen said the company’s aim was to cover “direct defence demand for tungsten,” while Rick Werner of Haynes Boone called part of the funding rush “very speculative.” Reuters

For Atlas, the tape is still thin. The company’s market value was about $21.8 million, and Investing.com showed an after-hours price of $4.36; a thin tape means fewer shares trade, so smaller orders can move the stock more sharply than they would at a larger company.

Atlas describes itself as a Brazil-focused exploration and development company with rare earths, graphite and uranium assets, and says its push is tied to artificial intelligence, energy transformation and defense uses. The company is not yet being valued like a scaled producer; it is being priced more like an option on future resource development.

The January Nasdaq debut set up the current U.S. market profile. Atlas said then it controlled more than 218,000 hectares of mineral rights in Brazil, and CEO Marc Fogassa said the listing would bring “enhanced visibility” and wider access to institutional investors. Atlas Critical Minerals

Analyst coverage is new but sparse. H.C. Wainwright began coverage in April with a Buy rating and a $13.75 price target; Atlas said the research was led by Heiko Ihle, who had made two site visits to the company’s Brazilian projects.

But the policy story does not remove mine risk or capital-market risk. In its prospectus, Atlas warned that no active, liquid market might develop; it also said the stock could be volatile, that it may need more capital, and that future financings could dilute holders. The downside case is plain: if exploration disappoints or funding tightens, the stock remains a small miner with little room for selling pressure.

The broader market backdrop is friendlier than Atlas’s own chart. U.S. stocks set records Thursday, with the S&P 500 up 0.6% at 7,563.63 and the Nasdaq Composite up 0.9% at 26,917.47, although small-cap mining shares often need company-level catalysts rather than just index strength.

That puts Friday’s early trade on two tracks: whether the defense-miner bid keeps pulling in buyers, and whether ATCX can separate itself from the pack with harder project evidence. For now, the verified news is more about the market around Atlas than a fresh operational update from Atlas itself.

Stock Market Today

  • AIM Movers: CelLBxHealth-AstraZeneca Deal, Borders & Southern Seeks Farm Out Partners
    May 29, 2026, 7:15 AM EDT. CelLBxHealth surged 47.8% after partnering with AstraZeneca as a qualified service provider for its drug pipeline. Europa Oil and Gas gained 6.67% following Equatorial Guinea farm out approval, pending Chinese government consent. Fletcher King shares rose 6.17% after Arrowsmith Partners adjusted its stake. Medpal AI jumped 6.12%, reporting £1.6m initial revenue and expansion into NHS dispensing hubs. Lansdowne Resources shares dropped 16% amid compensation claims over Barryroe field permit denial. Buccaneer Energy fell 8.33% on production drop due to floods but expects recovery in 2026. Borders & Southern Petroleum declined 3.7% with multiple farm out partners eyed amid Sea Lion prospect interest.